Pay in 4 interest-free payments of $7.37 Learn more
Ships within 48 hours · Estimated delivery Aug 26 - Aug 31
ZD: In the past 3 years, ZD received speaker or consultant honoraria and/or served on advisory boards at: Antabio, Foresee Pharmaceuticals, GlaxoSmithKline, Hippo-Dx, QPS-Netherlands, Sanofi-Genzyme-Regeneron, and Springer Media all outside the submitted work
DPP-4 Inhibitors: What Is Their Place in Therapy
Healthcare organizations are still monitoring changes in FDA guidance
Understanding the complex interactions between GLP-1RA medications, risk factors for PDAC, and pancreatic tumorigenesis will require the development of new preclinical models, which will be complementary to longer-term studies in humans
Medicare Part D plans are required to cover at least two drugs per class, so once a generic is available, your plan might move the brand-name version to a higher tier or require step therapy (try the generic first)
US$ 22.30
US$ 25.61
US$ 20.18
:max_bytes(150000):strip_icc()/GettyImages-1331502792-cdc8ea8d1bb3486d96111406aff3ae34.jpg)
US$ 25.69
